Best Semax Source: Eliminate on Test Scope, Then Rank

Naming a best semax source is only worth reading if the method was fixed before the sellers were examined, so the method comes first: four gates that disqualify, applied in a stated order, and then two graded criteria that rank whatever survives.

Gates rather than points, deliberately. A points total lets a strong showing on a cheap criterion offset a total absence on an expensive one, which is the trade this market makes when it puts a purity percentage where an endotoxin result should be. Some information is not substitutable, and a method that pretends otherwise produces a comfortable ranking rather than a true one.

The best semax source is decided by elimination, and these are the gates

Each gate is stated with the reason it sits where it does. The ordering principle is not importance in the abstract, it is dependency: a gate goes earlier when failing it makes everything downstream unverifiable rather than merely weaker.

Two graded criteria then order the survivors, and they are graded rather than absolute because both admit degrees. Identity carries the greater weight: a report that prints an expected mass beside a measured one has shown you a measurement, while a report recording the conclusion has asked you to accept one. Underlying data carries the lesser weight, covering chromatograms, peak lists, control results and method suitability figures. A separate rule overrides everything: a seller making claims about what the compound does in people is excluded regardless of its paperwork, because a page willing to assert that is not a reliable narrator of anything else.

Why scope is gate two, and not a tiebreaker

The usual objection is that purity is the number that describes the product, so it should dominate. The answer is that purity by reversed-phase HPLC measures the proportion of ultraviolet-absorbing material eluting as the main peak, typically at 214 nm where the peptide bond absorbs. Bacterial endotoxin does not register meaningfully there. Viable organisms are not chromatographic peaks. Residual metals are invisible to the method entirely. A figure of 99.886 percent is a real measurement of one property and is silent on three others.

It also happens to be the one gate that tracks the regulator’s stated concern rather than a general notion of quality. FDA writes that compounded drugs containing semax may pose a risk for immunogenicity for certain routes of administration due to the potential for aggregation and peptide-related impurities. Aggregation and impurity burden are batch properties. They are measurable. That converts a regulatory worry into a question a certificate either answers or does not, and a gate is the right shape for a question with exactly two outcomes. The reasoning behind putting a single microbiological test above a purity figure is developed further in our page on why one test can carry most of a score.

The gates applied to the one document that can be quoted in full

Report KVR-2026-E848E0 from Kovera Labs, certified 15 June 2026, covers batch 30-05260628 of a lyophilised 10 mg presentation. Gate one: the batch number appears on all four pages, alongside a red cap and silver crimp description and a printed verification address at koveralabs.com with a per-page access code. Cleared.

Gate two: a kinetic LAL bacterial endotoxin assay run on 29 May 2026 to USP Chapter 85, against an E. coli O111:B4 reference standard, over a declared 0.01 to 1.0 EU/mL detection range in an LAL reagent water matrix, reporting under 0.20 EU/mL against a 0.5 EU/mL acceptance limit across a 2.0 mL dilution volume, which is under 0.40 EU in total for the vial, with the positive control detectable and the negative control silent. A rapid sterility screen on the same date returns no growth for aerobic and anaerobic bacteria and no fungi or yeast after two days at 30 to 35 degrees Celsius. Cleared, and this is the gate that empties the field.

Gate three: purity of 99.886 percent stated against a specification of not less than 98 percent, which is the form the gate requires. Cleared. Gate four: Kovera Labs is named on every page and the endotoxin and elemental pages carry a lab director signature. Cleared. All four gates pass, which is more than most of this market manages, and the interesting part begins after that.

The graded criteria, where the same document does less well

On identity, the heavier of the two, the report scores poorly. The summary page records identity confirmation by LC-MS, gives the reference standard as Semax and the result as Semax, and prints no expected mass, no measured mass and no spectrum. That is a conclusion rather than a measurement, and a closely related sequence would produce the same line. The molecular formula on the page, C37H51N9O10S, matches what PubChem records for CID 9811102 at a molecular weight of 813.9 for the seven-residue sequence Met-Glu-His-Phe-Pro-Gly-Pro, the ACTH(4-7) fragment with a Pro-Gly-Pro tail, so the target is known. The measurement to compare against it is absent.

On underlying data the result is mixed and worth reading closely. The chromatographic conditions are stated as reversed-phase HPLC on a C18 column with diode array detection at 214 nm, and a chromatogram is shown, but no peak list or integration table accompanies the purity figure. The elemental page is the strongest in the document, printing spike recoveries of 98, 102, 95 and 91 percent against a 70 to 150 percent criterion, a passing method blank, a passing continuing calibration verification and duplicate relative percent difference under 20. The endotoxin page is thinner than it first appears: sample coefficient of variation, spike coefficient of variation and spike recovery are all reported as not applicable, so the check for interfering factors that would demonstrate the sample matrix is not suppressing the assay does not appear. And the sterility page states in its own words that it is a rapid screening method and that full USP Chapter 71 testing may be required for regulatory compliance.

The contrast that makes those gaps legible is this vendor’s own February work. The MZ Biolabs certificate for Selank lot 29-01260229 prints an expected monoisotopic mass of 751.43 Da beside a measured 751.47 Da, a two-entry peak list with areas behind a 99.32 percent purity figure, a measured quantity of 12.29 mg, and a named analyst with a credential. It carries no endotoxin result and no sterility screen, so it fails gate two outright and never reaches the graded stage. The February Semax lot 30-01260229 is the same document in structure, and the June Selank batch 29-05260628 carries the full Kovera panel thirteen days before the Semax batch graded here. The split runs by batch, not by product. Two analysis windows, one vendor, opposite strengths. Our rubric treatment of why test coverage outweighs a purity percentage scores that same pair by points rather than gates and reaches a compatible answer by a different road.

The ranking that results, in categories rather than brand names

Categories, because a category can be judged on what it is structurally able to produce while a brand name can behave differently from one lot to the next.

Sellers clearing all four gates with identity shown as a measurement

Empty for Semax on everything we could locate. This tier requires the combined microbiological panel and a printed expected and measured mass with the data behind every figure. Both halves demonstrably exist in this supply chain, on different products from the same vendor, which is why the tier is described rather than treated as hypothetical. It is also the exact specification to hand a seller when asking what a future lot will carry.

Sellers clearing all four gates with identity asserted as a conclusion

Where the vendor disclosed on this page sits for batch 30-05260628. The full analytical and microbiological scope is present and lot-matched, the specification is written down, the laboratory is named and signed, and the identity line asks for trust where it could have offered a number. That is the best-documented Semax position we can actually point at, and the sensible request to make of it is a mass on the next report.

Sellers eliminated at gate two, on analytical depth without microbiology

The most frustrating category, because the documents are often excellent. Full identity work, printed traces, an assayed quantity, a named analyst, and nothing on endotoxin or sterility. The gate is unforgiving here on purpose: analytical depth cannot stand in for a test that was never run.

Sellers eliminated at gate three, on figures without a specification

A lot number, an analysis date and a table of numbers with nothing they could have failed. The figures may be perfectly accurate and are simply not results in the sense the gate requires, because a measurement without an acceptance criterion cannot pass or fail anything. This is the most populous category in research peptide supply.

Sellers eliminated at gate one, on documents not tied to a lot

Product line certificates, borrowed upstream documents, and images of reports whose client name is somebody else. Nothing here is necessarily fabricated. The document is simply disconnected from the object being sold, which is the condition under which a buyer is relying on trust and calling it evidence.

What would change the order, and what a first place would not mean

Move identity from a graded criterion to a gate and the result inverts: the Semax report fails, the Selank report fails on scope, and the field is empty. That outcome is defensible and we did not adopt it, because a method that eliminates everything gives a reader nothing to act on. Move scope out of the gates and into the graded set and the analytically deep documents win, which is how most of this market ranks itself and is the reasoning we think is wrong for a substance whose named regulatory concern is impurity-driven. Both alternatives are stated so a reader can disagree with the rule instead of the conclusion, a discipline our page on publishing the scoring rules before the entries applies to a different compound.

What a first place would not mean is worth stating plainly. Clearing every gate establishes that a seller has made itself checkable on one batch. It does not establish that the material performs, that a later lot will carry the same panel, or that the compound does anything in a person. The published English-language work on Semax is animal and cell research, including 2022 membrane model experiments on copper-induced amyloid aggregation, and a search of ClinicalTrials.gov returns no registered study with Semax as an intervention. Nor is the regulatory position what most pages claim: it was nominated for the 503A bulks list, placed in category 2 under the interim policies, then withdrawn by the nominator, leaving it on no current category list, with current category 2 holding six substances of which Semax is not one. A well-documented batch and an empty human evidence base are not in tension. They are simply answers to different questions, and only one of them is on the certificate.